Department of Invasive Cardiology, Center of Postgraduate Medical Education, Warsaw, Poland.
Future Cardiol. 2021 Sep;17(6):1123-1130. doi: 10.2217/fca-2020-0171. Epub 2021 Jan 21.
In this preliminary study, we aimed to confirm the clinical utility and safety of the new noncompliant balloon catheter River NC (Balton, Poland). The primary study end point was to verify balloon diameters calculated in quantitative coronary angiography (QCA) to diameters prespecified by the manufacturer and obtained at given pressures in subjects undergoing percutaneous coronary interventions. Forty-two subjects were enrolled (73.8% multivessel disease; 40.5% type B1 lesions; 100% device success). No clinically significant differences between expected balloon diameters and QCA were registered in predilatation (2.36 ± 0.11 mm vs 2.43 ± 0.07 mm) and postdilatation (3.18 ± 0.19 mm vs 3.21 ± 0.31 mm). Our study results suggest that the River NC balloon is effective and safe. In the QCA evaluation, River NC balloon obtained prespecified diameters and lengths at applied pressures. Study registration: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (UR.D.WM.DNB.109.2019).
在这项初步研究中,我们旨在证实新型顺应性差的 River NC 球囊导管(波兰 Balton 公司生产)的临床实用性和安全性。主要研究终点是验证接受经皮冠状动脉介入治疗的患者在定量冠状动脉造影(QCA)中计算的球囊直径与制造商规定的直径和在特定压力下获得的直径是否一致。共纳入 42 例患者(73.8%为多血管病变;40.5%为 B1 型病变;100%器械成功率)。在预扩张(2.36±0.11mm 与 2.43±0.07mm)和后扩张(3.18±0.19mm 与 3.21±0.31mm)时,实际球囊直径与 QCA 预期直径之间无临床显著差异。我们的研究结果表明,River NC 球囊安全有效。在 QCA 评估中,River NC 球囊在施加的压力下获得了规定的直径和长度。研究注册:药品、医疗器械和杀生物剂注册办公室(UR.D.WM.DNB.109.2019)。